Rendering

Component: (Network and Table)
Network
100230 - Disclosure - Share-based Compensation (Tables)
(http://www.arcabiopharma.com/20161231/taxonomy/role/DisclosureShareBasedCompensationTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000907654 (http://www.sec.gov/CIK)
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
 
Estimated Weighted Average Grant Date Fair Value per Share

The Company granted options and awards for 487,700 and 52,801 shares of common stock in the years ended December 31, 2016 and 2015, respectively. The fair values of the majority of employee stock options granted in the years ended December 31, 2016 and 2015 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:

 

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

Expected term

 

5.7 years

 

 

5.8 years

 

Expected volatility

 

 

72

%

 

 

89

%

Risk-free interest rate

 

 

1.29

%

 

 

1.61

%

Expected dividend yield

 

 

0

%

 

 

0

%

Weighted-average grant date fair value per share

 

$

2.01

 

 

$

3.57

 

 

 

  
Summary of Stock Option Activities

A summary of ARCA’s stock option activities for the years ended December 31, 2016 and 2015, and related information as of December 31, 2016, is as follows:

 

 

 

Options Outstanding

 

 

 

Number

of Options

 

 

Weighted Average

Exercise

Price

 

 

Weighted Average Remaining Contractual Term

(in years)

 

 

Aggregate Intrinsic Value

(in thousands)

 

Options outstanding - December 31, 2014

 

 

152,584

 

 

$

20.20

 

 

 

 

 

 

 

 

 

Granted

 

 

21,492

 

 

 

4.92

 

 

 

 

 

 

 

 

 

Exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Forfeited and cancelled

 

 

(12,798

)

 

 

18.45

 

 

 

 

 

 

 

 

 

Options outstanding - December 31, 2015

 

 

161,278

 

 

$

18.30

 

 

 

6.97

 

 

$

—

 

Granted

 

 

487,700

 

 

 

3.22

 

 

 

 

 

 

 

 

 

Exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

Forfeited and cancelled

 

 

(19,349

)

 

 

28.70

 

 

 

 

 

 

 

 

 

Options outstanding - December 31, 2016

 

 

629,629

 

 

$

6.30

 

 

 

8.86

 

 

$

25

 

Options exercisable - December 31, 2016

 

 

181,518

 

 

$

13.19

 

 

 

7.46

 

 

$

—

 

Options vested and expected to vest -

       December 31, 2016

 

 

628,928

 

 

$

6.30

 

 

 

8.86

 

 

$

25

 

 

  
Summary of RSU Activity

A summary of RSU activity for the years ended December 31, 2016 and 2015 is presented below:

 

 

 

Restricted Stock Units Outstanding

 

 

 

Number

of Shares

 

 

Weighted

Average

Grant Date

Fair Value

 

RSUs outstanding - December 31, 2014

 

 

67,274

 

 

$

11.33

 

Granted

 

 

31,309

 

 

 

4.77

 

Vested and released

 

 

(26,669

)

 

 

10.75

 

Forfeited and cancelled

 

 

(9,555

)

 

 

10.90

 

RSUs outstanding - December 31, 2015

 

 

62,359

 

 

$

8.36

 

Granted

 

 

—

 

 

 

—

 

Vested and released

 

 

(31,149

)

 

 

8.85

 

Forfeited and cancelled

 

 

(471

)

 

 

4.69

 

RSUs outstanding - December 31, 2016

 

 

30,739

 

 

$

7.91

 

 

  
Summary of Non-cash, Share-based Compensation Expense

For the years ended December 31, 2016 and 2015, the Company recognized the following non-cash, share-based compensation expense (in thousands):

 

 

Years Ended

 

 

December 31,

 

 

2016

 

 

2015

 

Research and development

$

167

 

 

$

175

 

General and administrative

 

409

 

 

 

424

 

Total

$

576

 

 

$

599